TY  - JOUR
AU  - Hütter-Krönke, Marie Luise
AU  - Neagoie, Adela
AU  - Blau, Igor Wolfgang
AU  - Wais, Verena
AU  - Vuong, Lam
AU  - Gantner, Andrea
AU  - Ahn, Johann
AU  - Penack, Olaf
AU  - Schnell, Jacqueline
AU  - Nogai, Klaus Axel
AU  - Eberspächer, Bettina
AU  - Saadati, Maral
AU  - Benner, Axel
AU  - Bullinger, Lars
AU  - Döhner, Hartmut
AU  - Bunjes, Donald
AU  - Sala, Elisa
TI  - Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
JO  - Frontiers in immunology
VL  - 14
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2023-01011
SP  - 1174289
PY  - 2023
AB  - Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is approved and recommended for immunocompromised patients such as patients after allogeneic stem cell transplantation (allo-SCT). Since infections represent a relevant cause of transplant related mortality we analyzed the advent of immunization to SARS-CoV-2 vaccination in a bicentric population of allogeneic transplanted patients.We retrospectively analyzed data of allo-SCT recipients in two German transplantation centers for safety and serologic response after two and three SARS-CoV-2 vaccinations. Patients received mRNA vaccines or vector-based vaccines. All patients were monitored for antibodies against SARS-CoV2-spike protein (anti-S-IgG) with an IgG ELISA assay or an EIA Assay after two and three doses of vaccination.A total of 243 allo-SCT patients underwent SARS-CoV-2 vaccination. The median age was 59 years (range 22-81). While 85
KW  - COVID 19-vaccination (Other)
KW  - SARS-CoV-2 antibodies (Other)
KW  - SARS-CoV-2-vaccination (Other)
KW  - allogeneic stem cell transplantation (Other)
KW  - booster (Other)
KW  - humoral response (Other)
KW  - vaccine (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37207199
C2  - pmc:PMC10190126
DO  - DOI:10.3389/fimmu.2023.1174289
UR  - https://inrepo02.dkfz.de/record/276189
ER  -